AntibodyLimited DatastaleJunshi BiosciencesPhase 2
Toripalimab+cetuximab (Toripalimab+cetuximab)
Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab
#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting